Tilray Brands Reports Strong Q2 Earnings with $218 Million Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: NASDAQ.COM
- Record Revenue: Tilray reported a record revenue of $218 million for Q2 of fiscal 2026, surpassing analyst expectations, although the year-over-year growth of only 3% indicates limited momentum in a competitive market.
- Narrowed Net Loss: The company reduced its net loss to $43.5 million from $85.3 million in the prior year, despite a decline in gross margin from 29% to 26%, suggesting improved cost management that may bolster investor confidence.
- Expanded Market Opportunity: Following President Trump's executive order reclassifying cannabis as a Schedule 3 substance, Tilray is launching Tilray Medical USA to expand its medical cannabis operations in the U.S., aiming to broaden its product portfolio and reach a wider patient base through partnerships.
- Increased Competitive Pressure: While Tilray's opportunities in the U.S. market are growing, it faces intense competition from established multistate operators, and the ongoing federal illegality of cannabis may hinder its expansion capabilities, leading to potentially subpar financial performance over the next five years.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
